Table 4. Adverse events related to therapy.
| Adverse events | Any grade | Grade 3–4 | |||||
|---|---|---|---|---|---|---|---|
| TACE-HAIC group (n=32) | HAIC group (n=41) | P value | TACE-HAIC group (n=32) | HAIC group (n=41) | P value | ||
| All | 29 (90.6%) | 35 (85.4%) | 0.722 | 12 (37.5%) | 8 (19.5%) | 0.115 | |
| General symptoms | |||||||
| Fever | 15 (46.9%) | 9 (22.0%) | 0.043 | 3 (9.4%) | 2 (4.9%) | 0.648 | |
| General fatigue | 10 (31.3%) | 9 (22.0%) | 0.427 | 2 (6.3%) | 1 (2.4%) | 0.578 | |
| Gastrointestinal symptoms | |||||||
| Nausea/vomit | 18 (56.3%) | 21 (51.2%) | 0.814 | 4 (12.5%) | 4 (9.8%) | 0.493 | |
| Abdomen pain | 16 (50.0%) | 19 (46.3%) | 0.816 | 5 (15.6%) | 3 (7.3%) | 0.287 | |
| Anorexia | 8 (25.0%) | 11 (26.8%) | >0.999 | 0 | 0 | – | |
| Ascites | 2 (6.3%) | 1 (2.4%) | 0.578 | 0 | 0 | – | |
| Laboratorial indexes abnormalities | |||||||
| Elevated ALT level | 11 (34.4%) | 5 (12.2%) | 0.044 | 4 (12.5%) | 3 (7.3%) | 0.692 | |
| Neutropenia | 7 (21.9%) | 7 (17.1%) | 0.766 | 0 | 0 | – | |
| Anemia | 6 (18.8%) | 4 (9.8%) | 0.317 | 0 | 0 | – | |
| Thrombocytopenia | 9 (28.1%) | 10 (24.4%) | 0.791 | 4 (12.5%) | 2 (4.9%) | 0.394 | |
| Hypoalbuminemia | 4 (12.5%) | 3 (7.3%) | 0.692 | 1 (3.1%) | 0 | 0.438 | |
| Others | |||||||
| Hypertension | 5 (15.6%) | 6 (14.6%) | >0.999 | 0 | 0 | – | |
| Sensory neuropathy | 1 (3.1%) | 0 | 0.438 | 0 | 0 | – | |
TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; ALT, alanine aminotransferase.